Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,281 | $5,446 | $7,159 | $6,365 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Cost of Goods Sold | $3,525 | $4,501 | $4,825 | $4,332 |
| Gross Profit | $1,756 | $945 | $2,334 | $2,033 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| R&D Expenses | $212 | $185 | $252 | $221 |
| G&A Expenses | $145 | $145 | $146 | $142 |
| SG&A Expenses | $455 | $590 | $665 | $573 |
| Sales & Mktg Exp. | $309 | $445 | $519 | $430 |
| Other Operating Expenses | $348 | $1,031 | -$101 | $43 |
| Operating Expenses | $1,015 | $1,806 | $1,212 | $1,069 |
| Operating Income | $741 | -$861 | $829 | $227 |
| % Margin | 14% | -15.8% | 11.6% | 3.6% |
| Other Income/Exp. Net | -$15 | -$67 | $1 | -$5 |
| Pre-Tax Income | $726 | -$928 | $830 | $222 |
| Tax Expense | $101 | -$126 | $115 | -$11 |
| Net Income | $647 | -$783 | $727 | $241 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| Weighted Avg Shares Out | 1,467 | 1,467 | 1,467 | 1,467 |
| Weighted Avg Shares Out Dil | 1,467 | 1,467 | 1,467 | 1,467 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $24 | $54 | $55 |
| Interest Expense | $141 | $223 | $235 | $202 |
| Depreciation & Amortization | $331 | $385 | $318 | $307 |
| EBITDA | $1,198 | -$320 | $1,383 | $731 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |